Clinical Cutaneous Features of Patients Infected With SARS-CoV-2 Hospitalized for Pneumonia: A Cross-sectional Study.
COVID-19
dermatology
exanthema
pandemics
pneumonia
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
23
07
2020
accepted:
25
08
2020
entrez:
18
11
2020
pubmed:
19
11
2020
medline:
19
11
2020
Statut:
epublish
Résumé
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of a current pandemic worldwide. This virus can reach all organs and disturbs the immune system, leading to a cytokine storm in severe forms. We aimed to report cutaneous features among coronavirus disease 2019 (COVID-19) hospitalized patients. We performed a cross-sectional study on 1 given day among all patients hospitalized in acute care for COVID-19 and included all patients with cutaneous features. Follow-up 48 hours later was obtained. Among 59 adult patients hospitalized on the day of the study in an infectious diseases ward for SARS-CoV-2 infection who were confirmed by molecular assay and/or radiological findings (computed tomography scan), 40 were included. Several cutaneous manifestations were found: macular exanthema (80%), face edema (32%), livedo (13%), urticarial rash (8%), purpura (5%), oral lichenoid lesions (33%), and conjunctivitis (18%). Cutaneous biopsy was performed in 17 patients. Histological findings showed mast cell hyperplasia (100%), superficial perivascular infiltrate of lymphocytes (94%), and superficial edema (47%) consistent with capillary leak. Various dermatological signs can be encountered during COVID-19. A macular rash was the most frequent. All cutaneous features could be related to a vascular leak process.
Sections du résumé
BACKGROUND
BACKGROUND
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of a current pandemic worldwide. This virus can reach all organs and disturbs the immune system, leading to a cytokine storm in severe forms. We aimed to report cutaneous features among coronavirus disease 2019 (COVID-19) hospitalized patients.
METHODS
METHODS
We performed a cross-sectional study on 1 given day among all patients hospitalized in acute care for COVID-19 and included all patients with cutaneous features. Follow-up 48 hours later was obtained.
RESULTS
RESULTS
Among 59 adult patients hospitalized on the day of the study in an infectious diseases ward for SARS-CoV-2 infection who were confirmed by molecular assay and/or radiological findings (computed tomography scan), 40 were included. Several cutaneous manifestations were found: macular exanthema (80%), face edema (32%), livedo (13%), urticarial rash (8%), purpura (5%), oral lichenoid lesions (33%), and conjunctivitis (18%). Cutaneous biopsy was performed in 17 patients. Histological findings showed mast cell hyperplasia (100%), superficial perivascular infiltrate of lymphocytes (94%), and superficial edema (47%) consistent with capillary leak.
CONCLUSIONS
CONCLUSIONS
Various dermatological signs can be encountered during COVID-19. A macular rash was the most frequent. All cutaneous features could be related to a vascular leak process.
Identifiants
pubmed: 33204745
doi: 10.1093/ofid/ofaa394
pii: ofaa394
pmc: PMC7650967
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofaa394Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Références
J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
Biomed Pharmacother. 2015 Mar;70:213-6
pubmed: 25776503
J Eur Acad Dermatol Venereol. 2020 Jul;34(7):e306-e307
pubmed: 32330340
J Eur Acad Dermatol Venereol. 2020 Sep;34(9):e451-e452
pubmed: 32339344
Zhonghua Xue Ye Xue Za Zhi. 2020 Mar 28;41(0):E006
pubmed: 32220276
Indian J Dermatol. 2010;55(1):79-85
pubmed: 20418984
JAMA Ophthalmol. 2020 May 1;138(5):575-578
pubmed: 32232433
J Am Acad Dermatol. 2020 Aug;83(2):700
pubmed: 32283229
J Am Acad Dermatol. 2020 Jul;83(1):e61-e63
pubmed: 32339703
Curr Pharm Des. 2003;9(1):11-24
pubmed: 12570671
J Eur Acad Dermatol Venereol. 2020 Aug;34(8):e346-e347
pubmed: 32330324
J Am Acad Dermatol. 2020 Jul;83(1):280-285
pubmed: 32305439
J Eur Acad Dermatol Venereol. 2020 May;34(5):e212-e213
pubmed: 32215952
Circulation. 2020 Jul 7;142(1):68-78
pubmed: 32293910
Lancet Infect Dis. 2020 Apr;20(4):425-434
pubmed: 32105637
N Engl J Med. 2006 Feb 9;354(6):601-9
pubmed: 16467547
Clin Rev Allergy Immunol. 2017 Dec;53(3):452-468
pubmed: 28547523
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
J Eur Acad Dermatol Venereol. 2020 Jun;34(6):e250-e251
pubmed: 32294264
Comp Med. 2013 Feb;63(1):13-21
pubmed: 23561933
Lancet Infect Dis. 2020 Jun;20(6):697-706
pubmed: 32224310
Transl Res. 2020 Jun;220:1-13
pubmed: 32299776
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
N Engl J Med. 2020 Apr 23;382(17):e38
pubmed: 32268022
J Eur Acad Dermatol Venereol. 2020 May;34(5):e210-e211
pubmed: 32201983
Elife. 2015 Mar 18;4:
pubmed: 25783751
Ann Intern Med. 2010 Jul 20;153(2):90-8
pubmed: 20643990